EHA 2021 | Real-world analysis of safety and efficacy of romiplostim for ITP

Barbara Skopec • 28 May 2021

EHA 2021

PLATON

Barbara Skopec, MD, PhD, University Medical Centre Ljubljana, Ljubljana, Slovenia, shares the findings of a post-hoc analysis of the PLATON study, investigating the effectiveness and safety of romiplostim in patients with newly diagnosed, persistent and chronic immune thrombocytopenia (ITP). The analysis, which included data from 100 patients with ITP, reported that durable platelet response was achieved in 50% of newly diagnosed patients, 35% of patients with persistent ITP and 31% of patients with chronic ITP. Safety was comparable across all ITP groups. Overall, the study concluded that platelet response to romiplostim was consistent across the newly diagnosed, persistent and chronic ITP settings. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.